



710 0362 #5  
Attorney Docket No. MSK.P-013-2  
PATENT APPLICATION  
March 6, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Cheung, et al.  
Serial No. : 10/075,947  
Filing Date : 02/13/2002  
Title : Single Chain FV Constructs of Antiganglioside GD2 Antibodies  
Conf. No. : 9846

RESUBMISSION OF SEQUENCE LIST AND DISKETTE

Assistant Commissioner for Patents  
U.S. Patent and Trademark Office  
Washington, D.C. 20231

Sir:

On April 30, 2002 Applicants received a Notice to Comply with Requirements for Patent Applications which was mailed on April 26, 2002. A copy of the Notice is attached. On May 14, 2002 Applicants responded to the Notice by filing a Response to Notice to Comply, a paper copy and a machine readable copy of the sequence listing for this application as well as a Preliminary Amendment. The documents were received by the Patent Office as evidenced by the postcard receipt, a copy of which is also attached.

Hearing nothing further and in response to a status check, a call was placed to the Patent Office to inquire as to status on November 27, 2002. The Examiner handling this file indicated we should contact OIPE. Speaking with Preston Wallace we were advised that the last computer notation on July 2, 2002 indicated that the CRF did not match. That was all that he could

I hereby certify that this paper and the attachments named herein are being deposited with Federal Express in an envelope addressed to the Assistant Commissioner for Patents, U.S. Patents and Trademarks Office, 2011 South Clark Place, Customer Window, Crystal Plaza Two, Lobby, Rm. 1B03, Arlington, VA 22202 on 3/6/03.

Date

3/6/03


  
Linda L. Orr

ascertain. He suggested that we resubmit the CRF and Sequence Listing as it was evidently damaged in transit. This is the resubmission.

The undersigned hereby certifies that the enclosed paper copy of the Sequence Listing and the enclosed computer readable form have the same content. No new matter has been added. Please enter the paper copy into the application at the appropriate location.

Respectfully submitted,

OPPEDAHL & LARSON LLP

A handwritten signature in cursive script, appearing to read "Marina T. Larson", with a long horizontal flourish extending to the right.

Marina T. Larson, Ph.D.

Reg. No. 32,038

P.O. Box 5068

Dillon, CO 80435-5068

970-468-6600

#5



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/075,947	02/13/2002	Nai-Kong V. Cheung	MSK.P-013-2

021121  
OPPEDAHL AND LARSON LLP  
P O BOX 5068  
DILLON, CO 80435-5068



CONFIRMATION NO. 9846

## FORMALITIES LETTER



\*OC000000007968487\*

Date Mailed: 04/26/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE